Results 171 to 180 of about 6,619 (182)
Some of the next articles are maybe not open access.

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

New England Journal of Medicine, 2013
Donal J Sexton   +2 more
exaly  

Phase III Clinical Pharmacology Study of Tolvaptan

Cardiovascular Drugs and Therapy, 2011
Atsushi Hirayama   +2 more
exaly  

Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist—Pharmacology and Clinical Trials

Cardiovascular Drug Reviews, 2007
Hiroyuki Fujiki   +2 more
exaly  

Predictive Factors for Responders to Tolvaptan in Fluid Management After Cardiovascular Surgery

General Thoracic and Cardiovascular Surgery, 2017
Yoshiki Sawa   +2 more
exaly  

Tolvaptan in Later-Stage Polycystic Kidney Disease

New England Journal of Medicine, 2018
Christian De Tymowski   +2 more
exaly  

Con: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease-Do We Know All the Answers?

Nephrology Dialysis Transplantation, 2019
Alexander Paliege
exaly  

Effect of Grapefruit Juice on the Pharmacokinetics of Tolvaptan, a Non-Peptide Arginine Vasopressin Antagonist, in Healthy Subjects

European Journal of Clinical Pharmacology, 2012
Suresh Mallikaarjun, Patricia Bricmont
exaly  

Home - About - Disclaimer - Privacy